logo

Royality Med Pharmaceuticals Group

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymedgrp.com
mobile-logo
 

Artificial Intelligence



Fulfilling the Promise of Artificial Intelligence

Royality Med Pharmaceuticals Group (RMPG) is revolutionizing healthcare by leveraging advanced artificial intelligence (AI) technologies. AI provides powerful insights and efficiencies that assist physicians and enhance treatment options and patient outcomes.

Our data scientists are developing state-of-the-art technologies to enable faster, more informed decision-making across many areas of our business. AI empowers us to deliver solutions with greater speed and efficiency, making it an essential tool in the battle against disease.

AI in Drug Discovery: Exploring the Chemical Space

Discovering new drugs is a highly complex and time-intensive process. It involves screening vast libraries of small molecules to identify those that effectively bind to specific disease-related targets.

 

Artificial intelligence is transforming how potential drug compounds are discovered. At Royality Med Pharmaceuticals Group (RMPG), AI drives the search for novel drug targets, beginning with heart failure. By leveraging advanced technologies such as knowledge graphs for patient subtyping, in-silico target identification, and target ranking, we strive to deliver urgently needed treatments to patients faster and with greater accuracy.

 



Clinical Trials: New approaches, better results

Clinical trials represent the most time-intensive phase of drug development due to complex planning, rigorous design standards, and difficulties in patient recruitment. Royality Med Pharmaceuticals Group (RMPG) is leveraging artificial intelligence to streamline this process, enhancing both efficiency and safety.
Through the Future Clinical Trials initiative—a collaboration between Royality Med Pharmaceuticals Group (RMPG) in Finland, Aalto University, and Helsinki University Hospital—trial planning and execution are being revolutionized. By utilizing real-world, high-quality medical data, AI helps accurately identify suitable patients, enabling more effective patient classification. Its advanced ability to detect even rare side effects supports risk mitigation and leads to improved trial outcomes.

The partners are exploring ways to enhance clinical trial design using AI by incorporating external control groups drawn from historical, virtual, or synthetic datasets. By leveraging AI in this manner, we can expand traditional trial methodologies with innovative approaches that provide deeper insights into the effects of new drugs. This advancement holds promise for accelerating the delivery of new treatments to patients worldwide.

 

Medical Coding: Proprietary AI saves years of manual work

Royality Med Pharmaceuticals Group (RMPG) has leveraged natural language processing (NLP)—the technology powering large language models like GPT—for several years. NLP plays a critical role in medical coding, where data collected by physicians in case reports must be translated into standardized terms and categories for analysis and review. Performing this manually is tedious and time-consuming. RMPG uses a proprietary AI solution to address this challenge. Their large language model (LLM) processes vast amounts of medical information with 96 percent accuracy. To ensure accuracy, all AI-generated codes undergo a “four-eyes principle,” with human medical coders reviewing each suggestion. Since 2017, this approach has enabled RMPG to process millions of terms, accelerating clinical trials by approximately 170,000 hours—over 19 years—of saved time.

 



Medical Imaging: Easing the Workload of Radiologists


Beyond drug discovery, Royality Med Pharmaceuticals Group (RMPG) is leveraging AI to transform radiology. Partnering with Blackford Analysis, a recently acquired leader in imaging AI solutions, RMPG launched Calantic Digital Solutions in 2022. This platform offers a growing suite of AI-driven digital radiology applications designed to automate tedious tasks, speed up workflows, and enhance diagnostic accuracy.

By reducing radiologists' workload, Calantic Digital Solutions frees up valuable time, enabling radiology teams to serve more patients and provide timely, treatment-critical insights—from diagnosis through to care.

Towards an AI-powered future

Across Royality Med Pharmaceuticals Group (RMPG), numerous initiatives are underway to harness AI in our pursuit of innovation. The transformative impact of artificial intelligence today signals that we are only at the dawn of an era filled with extraordinary breakthroughs. Guided by our scientific principles and commitment to effective, sustainable, and accessible Health for All, RMPG’s scientists remain dedicated to exploring how this groundbreaking technology can be leveraged for even greater progress.

 


I would like to learn about Royality Med’s Pharmaceuticals Group discoveries to treat genetic diseases.


YES, TELL ME MORE